SIGNAL TRANSDUCTION BY NON-TRANSMEMBRANE PTP S
非跨膜 PTP S 的信号转导
基本信息
- 批准号:2093188
- 负责人:
- 金额:$ 30.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1988
- 资助国家:美国
- 起止时间:1988-12-01 至 1998-11-30
- 项目状态:已结题
- 来源:
- 关键词:Drosophilidae Schizosaccharomyces pombe Xenopus antisense nucleic acid bioassay biological signal transduction growth factor receptors keratinocyte laboratory mouse laboratory rabbit membrane proteins microinjections molecular cloning monoclonal antibody mutant neoplastic transformation neutralizing antibody phosphoprotein phosphatase phosphorylation protein isoforms receptor binding regulatory gene skin neoplasms
项目摘要
Control of protein tyrosyl phosphorylation is an important mechanism for
the regulation of cellular proliferation, the cell cycle,
differentiation, and cell death. Disregulation of these control
mechanisms can lead to neoplasia. Although much has been learned about
how protein tyrosine kinases (PTK) help determine the steady state level
of cellular phosphotyrosine, little is known about how phosphotyrosine
phosphatases (PTPs) contribute to this process, and virtually nothing is
known about how PTPs might contribute to disease. We will elucidate the
biological roles of two nontransmembrane PTPs, PTP1B and SHPTP2, cloned
during the first four years of this grant. Initial studies have
implicated PTP1B in control of the cell cycle and in cell death pathways.
In cycling cells, PTP1B resides in a high molecular weight complex on the
cytosolic surface of the endoplasmic reticulum, and undergoes cell cycle-
dependent modifications, including alternative splicing during G0 and G1,
and new serine phosphorylation at G2/M. However, in human keratinocytes
induced to undergo a terminal differentiation/cell death pathway by
calcium ionophores, PTP1B is cleaved and released as an active fragment
into the cytosol. This is reminiscent of a bacterial virulence
determinant that kills cells by dephosphorylating tyrosol phosphorylated
suggesting that PTP1B cleavage is important in keratinocyte cell death
pathways. SHPTP2, the apparent human homologue of Drosophila csw,
interacts directly with several ligand-activated growth factor receptor
and becomes tyrosyl phosphorylated in response to growth factor addition,
suggesting that it plays a critical role in early growth factor response.
In this grant, neutralizing monoclonal antibodies against PTP1B will be
generated to allow PTP1B mitotic phosphorylation sites will be mapped,
and the biologic role of PTP1B in mitosis explored by microinjection of
neutralizing antibodies and transient overexpression of wild type and
phosphorylation site mutant in mammalian cells and S. pombe. The precise
cleavage site of PTP1B in ionophore-treated keratinocytes will be defined
and the role of PTP1B cleavage in inducing cell death assessed in normal
cells and in skin cancers, which are refractory to induction of cell
death pathways. The precise sites of interaction of SHPTP2 with growth
factor receptors will be determined, and the effects of receptor binding
and tyrosyl phosphorylation on SHPTP2 enzymatic activity assessed. PDGF
receptor mutants that fail to bind SHPTP2 will be used to identify SHPTP2
downstream signaling targets. In collaborative studies, the ability to
SHPTP2 to complement csw mutations will be determined, and if
complementation is obtained, suppressor and potentiator screens in
Drosophila will be used to suggest other components of SHPTP2 signal
transduction pathways, Finally, a rapid in vitro bioassay for mapping
SHPTP2 functional domains and targets will be developed using FGF-induced
mesoderm induction in Xenopus as a model system. Since PTP1B and SHPTP2
appear to participate in control of all of the processes--the response
to growth factors, cell cycle control, control of differentiation, and
control of cell death--that are eluded by cancer cells, the results of
the proposed studies should yield critical information into how PTPs help
control these processes. Moreover, since tyrosyl phosphorylation is so
commonly disregulated in cancer cells, this work should have important
implication for understanding mechanisms of oncogenesis, and may suggest
new therapeutic approaches to combat neoplasia.
控制蛋白酪酶磷酸化是重要机制
细胞增殖的调节,细胞周期,
分化和细胞死亡。 忽略这些控制
机制可以导致肿瘤。 虽然已经了解了很多
蛋白质酪氨酸激酶(PTK)如何有助于确定稳态水平
细胞磷酸酪氨酸的磷酸酪氨酸如何知之甚少
磷酸酶(PTP)有助于此过程,几乎没有什么是
了解PTP可能如何促进疾病。 我们将阐明
克隆的两个非跨膜PTP和SHPTP2的生物学作用
在这笔赠款的前四年。最初的研究有
在控制细胞周期和细胞死亡途径中,涉及PTP1B。
在循环细胞中,PTP1B驻留在高分子量复合物上
内质网的胞质表面,并经历细胞周期 -
依赖性修改,包括G0和G1期间的替代剪接
G2/m处的新丝氨酸磷酸化。 但是,在人角质形成细胞中
诱导通过
钙离子载体,PTP1B被切割并释放为活性片段
进入细胞质。 这让人想起细菌毒力
通过去磷酸化的酪醇磷酸化来杀死细胞的决定因素
表明PTP1B裂解在角质形成细胞死亡中很重要
途径。 SHPTP2,果蝇CSW的明显人类同源物,
与几种配体激活的生长因子受体直接相互作用
并因响应生长因子的添加而变成酪酶磷酸化,
表明它在早期生长因子反应中起着至关重要的作用。
在这笔赠款中,针对PTP1B的中和单克隆抗体将是
生成以允许PTP1B有丝分裂磷酸化位点的映射,
PTP1B在微注射中探索的有丝分裂中的生物学作用
中和抗体和野生型的短暂过表达和
哺乳动物细胞和猪链球菌中的磷酸化位点突变体。 确切的
将定义经离子载体处理的角质形成细胞中PTP1B的切割位点
PTP1B裂解在正常情况下评估的细胞死亡中的作用
细胞和皮肤癌对诱导细胞的难治性
死亡道路。 SHPTP2与增长的相互作用的确切位置
将确定因子受体,以及受体结合的影响
评估了SHPTP2酶活性的酪酶磷酸化。 PDGF
无法结合SHPTP2的受体突变体将用于识别SHPTP2
下游信号目标。 在协作研究中
将确定SHPTP2以补充CSW突变,如果
获得互补,抑制器和增强器筛选
果蝇将用于建议SHPTP2信号的其他组件
转导途径,最后是用于映射的快速体外生物测定
SHPTP2功能域和目标将使用FGF诱导的
爪蟾中的中胚层诱导作为模型系统。 由于PTP1B和SHPTP2
似乎参与了所有过程的控制 - 回应
对于生长因素,细胞周期控制,分化的控制和
控制细胞死亡 - 被癌细胞避免了
拟议的研究应产生关键信息,以了解PTP的帮助
控制这些过程。 此外,由于酪酶磷酸化是如此
这项工作通常在癌细胞中不受控制,应该具有重要的
对理解肿瘤发生机制的影响,并可能表明
打击肿瘤的新治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BENJAMIN G. NEEL其他文献
BENJAMIN G. NEEL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BENJAMIN G. NEEL', 18)}}的其他基金
Molecular ontology of drug tolerant persisters in HER2 positive breast cancer - Resubmission - 1
HER2 阳性乳腺癌耐药者的分子本体论 - 重新提交 - 1
- 批准号:
10545025 - 财政年份:2022
- 资助金额:
$ 30.77万 - 项目类别:
Molecular ontology of drug tolerant persisters in HER2 positive breast cancer - Resubmission - 1
HER2 阳性乳腺癌耐药者的分子本体论 - 重新提交 - 1
- 批准号:
10391866 - 财政年份:2022
- 资助金额:
$ 30.77万 - 项目类别:
Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung Cancer
非小细胞肺癌中单独使用和联合使用 SHP2 抑制剂的反应和耐药性
- 批准号:
10531929 - 财政年份:2020
- 资助金额:
$ 30.77万 - 项目类别:
Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung Cancer
非小细胞肺癌中单独使用和联合使用 SHP2 抑制剂的反应和耐药性
- 批准号:
10316237 - 财政年份:2020
- 资助金额:
$ 30.77万 - 项目类别:
Human Shp2 (Ptpn11) mutations and cardiac valve development
人类 Shp2 (Ptpn11) 突变与心脏瓣膜发育
- 批准号:
7319031 - 财政年份:2007
- 资助金额:
$ 30.77万 - 项目类别:
Human Shp2 (Ptpn11) mutations and cardiac valve development
人类 Shp2 (Ptpn11) 突变与心脏瓣膜发育
- 批准号:
7629640 - 财政年份:2007
- 资助金额:
$ 30.77万 - 项目类别:
Human Shp2 (Ptpn11) mutations and cardiac valve development
人类 Shp2 (Ptpn11) 突变与心脏瓣膜发育
- 批准号:
7614852 - 财政年份:2007
- 资助金额:
$ 30.77万 - 项目类别:
Human Shp2 (Ptpn11) mutations and cardiac valve development
人类 Shp2 (Ptpn11) 突变与心脏瓣膜发育
- 批准号:
7789554 - 财政年份:2007
- 资助金额:
$ 30.77万 - 项目类别:
EM LOCALIZATION OF PTP1B & RTK & PTP1B INTERACTIONS
PTP1B 的电子显微镜定位
- 批准号:
7358054 - 财政年份:2006
- 资助金额:
$ 30.77万 - 项目类别:
相似国自然基金
裂殖酵母Schizosaccharomyces pombe Sap1和L-7C蛋白生物功能的研究
- 批准号:30770441
- 批准年份:2007
- 资助金额:32.0 万元
- 项目类别:面上项目